Background
MCDI has been funded by Marathon Oil, AMPCO, Noble Energy and the Government of Equatorial Guinea to lead the implementation of the Equatorial Guinea Malaria Vaccine Initiative (EGMVI). Implementing partners are Sanaria, Inc., the company developing a Plasmodium falciparum sporozoite (PfSPZ) malaria vaccine, the Ifakara Health Institute (IHI) of Tanzania, and the Ministry of Health and Social Welfare (MOHSW) of Equatorial Guinea (EG).
The goal of the EGMVI is to eliminate malaria from Bioko Island by combining the mass vaccination of Bioko's population based on a licensed PfSPZ vaccine with standard control measures implemented by the Bioko Island Malaria Control Project (BIMCP). The BIMCP, which is also implemented under the management of MCDI, works in close consultation with the National Malaria Control Program to deliver indoor residual spraying, long lasting insecticide treated nets, focal larval control, passive and active malaria diagnosis and treatment, behavior change communications and extensive monitoring and evaluation. The EGMVI will seek to carry out a series of scale-escalating and age-expanding vaccine trials and then, subject to the availability of a licensed and highly effective transmission blocking PfSPZ vaccine, to implement an Island-wide mass vaccination campaign aimed at eliminating malaria from the Island.
The first clinical trial with the PfSPZ vaccine in Bioko will be conducted in 2014, following a protocol that will be based on a similar trial conducted in Tanzania at the Ifakara Health Institute. IHI will provide technical assistance to the EGMVI to conduct the first clinical trial, supplying the Principal Investigator and other key clinical staff, and will work with the operational support of MCDI along with a team of Equatoguinean nationals to implement the trial. MCDI, with technical guidance from Sanaria and IHI and with technical support of WHO-AFRO, will be responsible for working with the Ministry of Health and Social Welfare to ensure that the conditions precedent for the first trial are put in place. These conditions includes, inter alia, establishing an Ethical Committee (EC) and National Regulatory Authority (NRA) in Equatorial Guinea to review and approve trial protocols and authorize the importation of clinical trial material.
In addition to setting up the appropriate ethics and regulatory authorities, the EGMVI is training Equatoguinean nationals to participate in the first clinical trial in Bioko Island. This team has participated in a training course at the IHI in Bagamoyo, Tanzania, to learn how clinical trials are conducted and managed, how Good Clinical Practice is adhered to, and how results are monitored. During the first trial, these individuals will be part of the Vaccine Implementation Team, along with four team members from IHI.. The objective is to prepare the Equatoguineans to take on direct roles in subsequent trials.
Subject to the successful implementation of the first trial, a series of age-expanding and scale-escalating trials are planned between 2014 and 2018. If, at the end of this process, the PfSPZ vaccine proves to be
This is initial version of the Scope of Work for the position; it may change slightly. highly effective and is licensed by the USFDA and is approved for use in Equatorial Guinea by the National Regulatory Authority, the EGMVI will be extended to carry out an Island-wide malaria vaccination campaign that will seek to eliminate malaria from the Island.
Qualifications
Roles and Responsibilities
Management
Coordination
Monitoring/evaluation
Planning for subsequent stages
Line of Authority
Location
To apply
Qualified interested parties should submit their CV detailing relevant experience, a 1420 biodata sheet, and the names and contact information for at least three references familiar with the applicant's skills and work (preferably individuals who are or have been supervisors) to: mcdjobs@mcd.org
The Subject line should read EGMVI Malaria Vaccine Project Specialist